Stockreport

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo!...

Kodiak Sciences Inc  (KOD) 
Last kodiak sciences inc earnings: 11/12 05:30 am Check Earnings Report
PDF tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a =2-step improvement in diabetic retinopathy severity score (DRSS) compared [Read more]